Search

Displaying results 4051 - 4060 of 8469 in total
  1. Drug

    Ethionamide

    go.drugbank.com/drugs/DB00609
    ApprovedInvestigationalWithdrawn

    A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)

  2. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

  3. Drug

    Velusetrag

    go.drugbank.com/drugs/DB12702
    Investigational

    Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. … Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders.

  4. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib has a monoisotopic molecular weight of 525.2 Da. … The usage of the INN stem '-rasib' in the name indicates that Opnurasib is a Ras protein inhibitor.

  5. Drug

    Gadoteric acid

    go.drugbank.com/drugs/DB09132
    ApprovedInvestigational

    [A263136] Gadoterate meglumine has one of the highest thermodynamic stability, apparent stability, and kinetic stability, partly due to its macrocyclic structure, and thus has a more favorable safety profile

  6. Drug

    Setiptiline

    go.drugbank.com/drugs/DB09304
    Experimental

    Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).

  7. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

  8. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting

  9. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  10. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneratio...